Request for expedited Result

Similar documents
Requisition for DNA Testing. Reason for Referral: Patient Information: INCOMPLETE REQUESTS WILL BE BANKED. Test Requests: Sample Collection:

Epilepsy. Genetic Test Submission Guide. 2. Samples. 1. Forms. 3. Ship RESULTS. impactgenetics.com

Targeted Genes and Methodology Details for Epilepsy/Seizure Genetic Panels

ERN EpiCARE. A European Reference Network for Rare and Complex Epilepsies. Petr Marusic Motol University Hospital, Prague

Subject ID: Date Test Started: Specimen Type: Peripheral Blood Date of Report: Date Specimen Obtained:

MOLECULAR SERVICES. mlabs.umich.edu

A European Reference Network for rare and complex epilepsies. J Helen Cross Coordinator

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION

Family Education and Support

Genetics & CMT Q&A Questions from the CMTA Genetics & CMT Discussion Forum

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

The benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide

Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective

Learn your genetic risk for the most common hereditary cancers.

GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer

LMM / emerge III Network Reference Sequences October 2016 LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene

Illumina Clinical Services Laboratory

The Next Generation of Hereditary Cancer Testing

GENETICS IN HEREDITARY NEUROPATHY

devseek (Sequence(Analysis(Panel(for(Neurodevelopmental(Disorders

INVITAE METABOLIC DISORDERS AND NEWBORN SCREENING GENE PANEL TESTS

A guide to genetic testing for hereditary cancers

Dr. Sarah Weckhuysen, MD, PhD. Neurogenetics Group, VIB-Department of Molecular Genetics University of Antwerp, Belgium

GYNplus. genetic testing for hereditary ovarian and/or uterine cancer

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Genetic testing for hereditary cancer

Test Information Sheet

Corporate Medical Policy

A Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You?

Assessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18

patient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention

Versus. Cancer genomics Competitive Analysis

Enabling Informed Clinical Decisions with Deep Insights. Routine Multi-gene Testing for Inherited Neuromuscular Disorders

Why Test for Hereditary Cancer in Preventive Care?

patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention

Clinical Laboratory Fee Schedule CY 2015 Updates June 9, 2014

PRICE AND TEST LIST January 4, 2018 (by Test Code)

Germline Testing for Hereditary Cancer with Multigene Panel

Genetic Risk Assessment for Cancer

Genetic testing and pancreatic disease

TGL clinical User Guide

MSI positive MSI negative

Genetics & Precision Medicine Cancer Care

Accel-Amplicon Panels

Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing.

Myriad Financial Assistance Program (MFAP)

Dr. Sarah Weckhuysen, MD, PhD. Neurogenetics Group, VIB-Department of Molecular Genetics University of Antwerp, Belgium

Family Assessment. Objectives. Comprehensive Family History Important Inexpensive Underutilized genetic tool

PRICE AND TEST LIST August 24, 2018 (by Test Code)

Enabling Personalized

The Role of genetic Testing for Inherited Prostate Cancer Risk

Utility of Microarrays in Molecular Genetics

Understanding Your Positive Result. A guide to understanding your risk and taking action

BRCAplus. genetic testing for hereditary breast cancer

PROVIDER POLICIES & PROCEDURES

Epilepsie & ernstige mentale retardatie: (nieuwe) genen en genotype-fenotype correlatie

Plasma-Seq conducted with blood from male individuals without cancer.

Whole exome sequencing Gene package Epilepsy version 1,

Are you at risk of Hereditary Cancer? Your Guide to the Answers

Informed Consent Columbia Whole Genome or Whole Exome Sequencing

Hereditary Cancer Products

Genetic Testing for Familial Gastrointestinal Cancer Syndromes. C. Richard Boland, MD La Jolla, CA January 21, 2017

OncoGeneDx Test Requisition Form

Division of Genomic Diagnostics CANCER GENOMIC TEST REQUISITION Page 1 of 6

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Hereditary Cancer. Genetic Testing Services. The GeneDx Experience

Genetics and Cancer Care. Cynthia Forster-Gibson, MD, PhD and Loren Mackay- Loder, MSc Genetics Program, THP

Corporate Medical Policy

Genetic Cancer Susceptibility Panels Using Next Generation Sequencing

NutraHacker. Carrier and Drug Response Report for Customer: b2b0b618-db91-447c-9470-ff7b79ae147d. Instructions:

DISEASE / DISORDER Price Routine TAT (Calendar Days) Achondroplasia + Hypochondroplasia FGFR3 Common mutations in FGFR3

OncoGeneDx Test Requisition Form

number of of condition inheritance

CHRONIC MYELOGENOUS LEUKEMIA

Personalised medicine: Past, present and future

TECHNICAL NOTICE. The CPT coding in this notice is effective January 1, 2013 and replaces the coding currently in use for these assays

OXFORD MEDICAL GENETICS LABORATORIES CURRENT DISEASE SERVICES APRIL 2018

Division of Genomic Diagnostics GENOMIC DIAGNOSTICS TEST REQUISITION *For Cancer tests please use the Cancer Test Requisition.

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Lab Prior Authorization

Neurogenetics User Manual

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

UKGTN Testing Criteria

Genetic Cancer Susceptibility Panels Using Next Generation Sequencing

Test Information Sheet

Jennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA

Division of Genomic Diagnostics GENOMIC DIAGNOSTICS TEST REQUISITION *For Cancer tests please use the Cancer Test Requisition.

Use of panel tests in place of single gene tests in the cancer genetics clinic

Objectives. Genetics in Cancer Treatment and Prevention. Genes

LABHORIZONS. New Procedures A NEWSLETTER FOR CLIENTS

UKGTN Testing Criteria

DNA Genetic Cancer Risk Test. Test Report

DISEASE / DISORDER Price Routine TAT (Calendar Days) Achondroplasia + Hypochondroplasia FGFR3 Common mutations in FGFR3

IntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.

Genetic Risk Assessment for Cancer

Transcription:

London Health Sciences Centre Molecular Genetics Laboratories Requisition for DNA Testing DACC002 REV 20170815 AUTHORIZED SIGNATURE IS REQUIRED INCOMPLETE REQUESTS WILL BE BANKED Molecular Genetics Laboratory Victoria Hospital, Room B10-123A, 800 Commissioners Road East, Ph: (519) 685-8122 London Ontario, N6A 5W9 Fax: (519) 685-8279 Reason for Referral: Diagnostic Testing Affected Unaffected Carrier testing/known Family Mutation Name of Index Case in the Family: D.O.B. yy /_mm_/_dd_ (include copy of report) Relationship to this patient: Gene: Mutation: RefSeq:NM Prenatal Diagnosis DNA Banking RNA Banking Referral to an outside Laboratory must specify lab: Patient s Name: Birthdate: _ yyyy / _mm_ / _dd_ Sex: Patient s Address: Health Card #: Test Requests: Use attached menu to select panels or individual genes. Panels, sub- panels or individual genes may be selected using the checkbox adjacent to the item of interest. Sample Collection: Date Drawn: _yyyy_/_mm_/_dd EDTA blood (lavender top)(min. 2 ml at room temp) EDTA bone marrow (lavender top)(min. 2ml at room temp) DNA (100ng to 1ug) ug Fresh/Frozen Tissue (provide tissue source) Formalin fixed paraffin embedded tissue(ffpe) (slides preferred) Other Clinical diagnostics and Family History: Request for expedited Result Pregnancy (L.M.P. yy / mm / dd_)_ Medical intervention(specify with date): yy /_mm_/_dd AUTHORIZED SIGNATURE (required): Referring physician: (Please Print) Name: Address: Tel ( ) Fax ( ) e-mail address: Lab use only Received date: Notes: Signature (required) CC report to: Name: Address: Tel ( ) Fax ( ) NS7468 (2017/08) Page 1 of 5

FOR SAMPLE REQUIREMENTS SEE: http://www.lhsc.on.ca/lab/molegen/index.htm Patient s Name: Molecular Genetics Laboratory Victoria Hospital, Room B10-123A, 800 Commissioners Road East, Ph: (519) 685-8122 London Ontario, N6A 5W9 Fax: (519) 685-8279 Birthdate: _ yy / mm_ / dd NGS Panels (includes deletion/duplication analysis) Hereditary Cancer (if patient meets OBSP criteria please use provincial cancer requisition) Hereditary Cancer - Comprehensive (30) APC (incl. 5 UTR), ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, CTNNA1, EPCAM, GREM1, MLH1 (incl. 5 UTR), MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLE, POLD1, PTEN (incl. 5 UTR), RAD51C, RAD51D, SDHB, SMAD4, STK11, TP53 Hereditary Cancer - High Penetrance (16) APC (incl. 5 UTR), ATM, BRCA1, BRCA2, CDH1, CHEK2, EPCAM, MLH1 (incl. 5 UTR), MSH2, MSH6, MUTYH, PALB2, PMS2, PTEN (incl. 5 UTR), STK11, TP53 Hereditary Cancer - Breast/Ovarian (19) ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1 (incl. 5 UTR), MSH2, MSH6, NBN, PALB2, PMS2, PTEN (incl. 5 UTR), RAD51D, RAD51C, STK11 TP53 Hereditary Cancer - Colorectal/Gastric Cancer (20) APC (incl. 5 UTR), BMPR1A, CDH1, CDK4, CHEK2, CTNNA1, EPCAM, GREM1, MLH1 (incl. 5 UTR), MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN (incl. 5 UTR), SDHB, SMAD4, STK11, TP53 Hereditary Cancer - individual selections APC (incl. 5 UTR) ATM BARD1 BMPR1A BRCA1 BRCA2 BRIP1 CDH1 CDK4 CDKN2A CHEK2 CTNNA1 EPCAM GREM1 MLH1 (incl. 5 UTR) MSH2 MSH6 MUTYH NBN PALB2 PMS2 POLD1 POLE PTEN (incl. 5 UTR) RAD51C RAD51D SDHB SMAD4 STK11 TP53 Charcot Marie Tooth Charcot Marie Tooth, HNPP - Comprehensive (34) AARS, AIFM1, DNAJB2, DYNC1H1, EGR2, FGD4, FIG4, GARS, GDAP1, GJB1, HSPB1, HSPB8, IGHMBP2, KIF1B, LITAF, LMNA, LRSAM1, MARS, MED25, MFN2, MPZ, MTMR2, NDRG1, NEFL, PDK3, PMP22, PRPS1, PRX, RAB7A, SBF2, SH3TC2, SPTLC1, TRPV4, TTR Charcot Marie Tooth - Type1 (10) EGR2, FIG4, GDAP1, GJB1, LITAF, MPZ, NEFL, PMP22, PRX, SH3TC2 Charcot Marie Tooth - Type2 (28) AARS, AIFM1, DNAJB2, DYNC1H1, FGD4, GARS, GDAP1, GJB1, HSPB1, HSPB8, IGHMBP2, KIF1B, LMNA, LRSAM1, MARS, MED25, MFN2, MPZ, MTMR2, NDRG1, NEFL, PDK3, PRPS1, RAB7A, SBF2, SPTLC1, TRPV4, TTR Charcot Marie Tooth: individual selections AARS AIFM1 DNAJB2 DYNC1H1 EGR2 FGD4 FIG4 GARS GDAP1 GJB1 HSPB1 HSPB8 IGHMBP2 KIF1B LITAF LMNA LRSAM1 MARS MED25 MFN2 MPZ MTMR2 NDRG1 NEFL PDK3 PMP22 PRPS1 PRX RAB7A SBF2 SH3TC2 SPTLC1 TRPV4 TTR Mitochondrial Genome and Depletion/Integrity panel Mitochondrial Genome and Depletion/Integrity Panel (56) Mitochondrial encoded genes: ATP6, ATP8, COX1, COX2, COX3, CYTB, ND1, ND2, ND3, ND4, ND4L, ND5, ND6, RNR1, RNR2, TRNA, TRNC, TRND, TRNE, TRNF, TRNG, TRNH, TRNI, TRNK, TRNL1, TRNL2, TRNM, TRNN, TRNP, TRNQ, TRNR, TRNS, TRNS2, TRNT, TRNV, TRNW, TRNY Nuclear encoded genes: APTX, DGUOK, DNA2, FBXL4, GFER, MGME1, MPV17, OPA1, OPA3 (isoform A & B), POLG, POLG2, RRM2B, SLC25A4, SPG7 (isoform1 & 2), SUCLA2, SUCLG1, TK2, TWNK, TYMP Mitochondrial Genome and Depletion and Integrity - Individual selections Mitochondrial encoded genes: ATP6, ATP8, COX1, COX2, COX3, CYTB, ND1, ND2, ND3, ND4, ND4L, ND5, ND6, RNR1, RNR2, TRNA, TRNC, TRND, TRNE, TRNF, TRNG, TRNH, TRNI, TRNK, TRNL1, TRNL2, TRNM, TRNN, TRNP, TRNQ, TRNR, TRNS, TRNS2, TRNT, TRNV, TRNW, TRNY, NS7468 (2017/08) Page 2 of 5

Nuclear encoded genes: APTX, DGUOK, DNA2, FBXL4, GFER, MGME1, MPV17, OPA1, OPA3 (isoform A & B), POLG, POLG2, RRM2B, SLC25A4, SPG7 (isoform1 & 2), SUCLA2, SUCLG1, TK2, TWNK (C10orf2), TYMP Cancer Hotspot Panel v2 (Ion Ampliseq ) (Tumour FFPE samples only) ERAS (KRAS, NRAS) BRAF EGFR FULL screen (2800 COSMIC mutations, research only) Single Genes by NGS(includes deletion/duplication analysis) ACADM - Medium Chain Acyl CoA Dehydrogenase (MCAD) GJB2 (CX26) / GJB6 (CX30) - Recessive Deafness MECP2 - RETT Syndrome MEN1 - Multiple Endocrine Neoplasia Type 1 NOTCH3 - CADASIL TP53 - Li-Fraumeni Syndrome RET - Multiple Endocrine Neoplasia Type 2 / FMTC SCN4A - Paramyotonia Congenita SPTLC1 - Hereditary Sensory Neuropathy NPC1 Niemann-Pick Disease 1 NPC2 Niemann-Pick Disease 2 ARSA Metachromatic Leukodystrophy CTNS - Cystinosis CLN2 Batten Disease CLN3 - Batten Disease OTC- Ornithine Transcarbamylase ARG1 Arginase Deficiency Targeted assays BCR-ABL CML minimal residual disease (quantitative RT-PCR) B-Cell Clonality (Lymphoma) (fragment analysis) T-Cell Clonality (Lymphoma) (fragment analysis) CFTR - Cystic Fibrosis-70 mutation screen (Mass Array) JAK2-p.V617F - Myeloproliferative disorders (quantitative PCR) F2 - Prothrombin G20210A (F2:c.97G>A) (Mass Array) F5 - Factor V Leiden (F5:p.R534Q) (Mass Array) HFE - Hemochromatosis p.c282y and p.h63d (Mass Array) MCC/Identity testing- Maternal cell contamination/ tissue contamination studies (fragment analysis) NS7468 (2017/08) Page 3 of 5

NGS Panels for Research Purposes Only (includes deletion/duplication analysis) Epilepsy (Available for research purposes only) Epilepsy: Comprehensive (69) ALDH7A1, AMT, ARX, ASAH1, ATP1A2, ATP1A3, CDKL5, CERS1, CHD2, CHRNA7, CNTNAP2, CSTB, DNM1, DOCK7, EPM2A, FOLR1, FOXG1, GAMT, GATM, GLDC, GOSR2, GRIN2A, GRIN2B, HCN1, KCNC1, KCNJ10, KCNJ11, KCNQ2, KCNQ3, KCNT1, KCTD7, LMNB2, MBD5, MECP2, MEF2C, MOCS1, NECAP1, NEU1, NHLRC1, NRXN1, PCDH19, PHGDH, PLCB1, PNKP, PNPO, POLG, PRICKLE2, PRRT2, PSAT1, PSPH, SCARB2, SCN1A, SCN1B, SCN2A, SCN8A, SCN9A, SLC2A1, SLC6A8, SLC9A6, SPTAN1, STXBP1, SUOX, SYNGAP1, TBC1D24, TCF4, TSC1, TSC2, UBE3A, ZEB2 Epilepsy - Management Impact (16) ALDH7A1, AMT, FOLR1, GAMT, GATM, GLDC, MOCS1, PHGDH. PNPO, POLG, PSAT1, PSPH SCN1A, SLC2A1, SLC6A8, SUOX Epilepsy - Progressive myoclonic (12) ASAH1, CERS1, CSTB, EPM2A, GOSR2, KCNC1, KCTD7, LMNB2, NEU1, NHLRC1, PRICKLE2, SCARB2 Epilepsy - Severe Phenotype (19) ARX, CDKL5, CHD2, DNM1, DOCK7, GRIN2A, GRIN2B, HCN1, KCNQ2, MECP2, MEF2C, NECAP1, PCDH19, SCN1B, SCN2A, SCN8A, SPTAN1, STXBP1, SYNGAP1 Epilepsy - Syndromes of Infancy (22) ATP1A2, ATP1A3, CHRNA7, CNTNAP2, FOXG1, KCNJ10, KCNJ11, KCNQ3, KCNT1, MBD5, NRXN1, PLCB1, PNKP, PRRT2, SCN9A, SLC9A6, TBC1D24, TCF4, TSC1, TSC2, UBE3A, ZEB2 Epilepsy - Individual selections ALDH7A1 AMT ARX ASAH1 ATP1A2 ATP1A3 CDKL5 CERS1 CHD2 CHRNA7 CNTNAP2 CSTB DNM1 DOCK7 EPM2A FOLR1 FOXG1 GAMT GATM GLDC GOSR2 GRIN2A GRIN2B HCN1 KCNC1 KCNJ10 KCNJ11 KCNQ2 KCNQ3 KCNT1 KCTD7 LMNB2 MBD5 MECP2 MEF2C MOCS1 NECAP1 NEU1 NHLRC1 NRXN1 PCDH19 PHGDH PLCB1 PNKP PNPO POLG PRICKLE2 PRRT2 PSAT1 PSPH SCARB2 SCN1A SCN1B SCN2A SCN8A SCN9A SLC2A1 SLC6A8 SLC9A6 SPTAN1 STXBP1 SUOX SYNGAP1 TBC1D24 TCF4 TSC1 TSC2 UBE3A ZEB2 Lysosomal Storage Disorders (Available for research purposes only) Lysosomal Storage Disorders (50) AGA, ARSA, ARSB, ASAH1, CLN3, CLN5, CLN6, CLN8, CTNS, CTSA, CTSD, CTSK, DNAJC5, FUCA1, GAA, GALC, GALNS, GBA, GLA, GLB1, GM2A, GNPTAB, GNPTG, GNS, GRN, GUSB, HEXA, HEXB, HGSNAT, HYAL1, IDS, IDUA, LAMP2, LIPA, MAN2B1, MANBA, MCOLN1, MFSD8., NAGA, NAGLU, NEU1, NPC1, NPC2, PPT1, PSAP, SGSH, SLC17A5, SMPD1, SUMF1, TPP1 Lysosomal Storage Disorders - Individual selections AGA ARSA ARSB ASAH1 CLN3 CLN5 CLN6 CLN8 CTNS CTSA CTSD CTSK DNAJC5 FUCA1 GAA GALC GALNS GBA GLA GLB1 GM2A GNPTAB GNPTG GNS GRN GUSB HEXA HEXB HGSNAT HYAL1 IDS IDUA LAMP2 LIPA MAN2B1 MANBA MCOLN1 MFSD8 NAGA NAGLU NEU1 NPC1 NPC2 PPT1 PSAP SGSH SLC17A5 SMPD1 SUMF1 TPP1 Urea Cycle Disorders (Available for research purposes only) Urea Cycle Disorders Panel (13) ARG, ASL, CA5A, SLC25A13, ASS1, GLUL, CPS1, SLC25A15, SLC25A2, GLUD1, SLC7A7, OTC, CPS1 Urea Cycle Disorders- Individual selections ARG ASL CA5A SLC25A13 ASS1 GLUL CPS1 SLC25A15 SLC25A2 GLUD1 SLC7A7 OTC CPS1 NS7468 (2017/08) Page 4 of 5

Hyperferritinemia (Available for research purposes only) Hyperferritinemia Panel (15) ALAS2, B2M, CDAN1, CP, FTH1, FTL, HAMP, HFE, HFE2, SEC23B, SLC25A38, SLC40A1, STEAP3, TF, TFR2 Hyperferritinemia- Individual selections ALAS2 B2M CDAN1 CP FTH1 FTL HAMP HFE HFE2 SEC23B SLC25A38 SLC40A1 STEAP3 TF TFR2 NS7468 (2017/08) Page 5 of 5